Sign in
Taking peopleNo phase

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

Key facts

Who runs it
Implantica CE Reflux Ltd.
Where
Germany, Italy, Norway, and Switzerland6 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
2,500 people, planned
Started
20 Feb 2023
Expected to end
31 Dec 2029
Type of study
Observational, 2 groups
Treatments tested
  • RefluxStop implantation
  • Nissen fundoplication
Record updated
1 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Willing and able to provide informed consent and to participate in the registry study,
  • Patient's age ≥ 18 years or according to local legal age of adulthood if older,
  • Documented GERD present for > 6 months,
  • Patient has a 24-hour pH monitoring proven GERD with pH and/or impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be <4 for >4.5% of time during a 24-hour monitoring and/or total reflux episodes of acid >55 or weakly acid >26 for >5 seconds at 5 cm above LES)
  • Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator

Who cannot take part

  • History of bariatric surgery wherein the stomach fundus has been extirpated,
  • Known sensitivity or allergies to silicone materials,
  • Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement)
  • Presence of para-esophageal hernia or sliding hernia > 3 centimeters,
  • Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed,
  • Female patients who are pregnant or nursing,
  • Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU)

This trial is currently available in Italy, Norway, and Switzerland.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

The 2 groups in the trial

  • RefluxStop patients

    Treatment: RefluxStop implantation

  • Nissen fundoplication patients

    Treatment: Nissen fundoplication

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Post-market Registry Study to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
Record updated
1 April 2025